Standpoint Research Reiterates a 'Buy' on Teva Pharma (TEVA); Issues of Uncertainty Overblown

Standpoint Research reiterates a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target range $55-$65.

Analyst, Ronnie Moas, said, "Teva is one of our favorite stocks in the Healthcare sector. The stock ranks # 1 versus 180 names according to our 155-variable computer model and passes our fundamental and subjective overlays with very high marks as well...TEVA is currently trading at just 7X earnings estimates for next year and looks even more attractive on a DCF analysis."

"First of all, the depressed multiple has little to do with the Israel-Iran tension. Even if a war broke out, the TEVA top line would not be impacted by more than 2%. TEVA has back-up facilities around the world that can easily pick up the slack in a worst case scenario."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $43.29 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings
• Reading (RDI) Tops Q2 EPS by 4c